Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)

Peiffer, Lauren B.; White, James R.; Jones, Carli B.; Slottke, Rachel; Ernst, Sarah E.; Moran, Amy E.; Graff, Julie N.; Sfanos, Karen S.

doi:10.1016/j.neo.2022.100822

Cited by 27 publications

(20 citation statements)

References 54 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aforementioned study observed a correlation between the abundance of Streptococcus salivarius in fecal samples and treatment response. It is possible that tumor type is also associated with the mechanisms through which gut microbiota affect ICIs' therapy (74). Additionally, the study design and potential confounding factors may have contributed to these findings.…”

Section: Erysipelotichaceaementioning

confidence: 99%

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Jiang,

Zhang

2024

Oncol Lett

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are commonly utilized in tumor treatment. However, they still have limitations, including insufficient effectiveness and unavoidable adverse events. It has been demonstrated that gut microbiota can influence the effectiveness of ICIs, although the precise mechanism remains unclear. Gut microbiota plays a crucial role in the formation and development of the immune system. Gut microbiota and their associated metabolites play a regulatory role in immune balance. Tumor occurrence and development are linked to their ability to evade recognition and destruction by the immune system. The purpose of ICIs treatment is to reinitiate the immune system's elimination of tumor cells. Thus, the immune system acts as a communication bridge between gut microbiota and ICIs. Varied composition and characteristics of gut microbiota result in diverse outcomes in ICIs treatment. Certain gut microbiota-related metabolites also influence the therapeutic efficacy of ICIs to some extent. The administration of antibiotics before or during ICIs treatment can diminish treatment effectiveness. The utilization of probiotics and fecal transplantation can partially alter the outcome of ICIs treatment. The present review synthesized previous studies to examine the association between gut microbiota and ICIs, elucidated the role of gut microbiota and its associated factors in ICIs treatment, and offered direction for future research.

show abstract

Section: Erysipelotichaceaementioning

confidence: 99%

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Jiang,

Zhang

2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…A recent study by Peiffer et al, exploring the role of commensal genitourinary microbiota composition on tumor response to ICI, was performed to obtain the profile of the microbiota composition in a cohort of 23 patients with metastatic CRPC progressing in enzalutamide and treated with ICI pembrolizumab [ 144 ]. The authors investigated the α- and ß-diversities of the fecal samples collected before and after pembrolizumab treatment and calculated the integrated index reported as associated with checkpoint inhibitor response.…”

Section: Developing Therapeutic Applications Targeting the Microbiomementioning

confidence: 99%

“…In patients responding to pembrolizumab, the oral bacterium Streptococcus salivarius was increased, and the gut bacterium Akkermansia muciniphila was depleted. The integrated index showed no relationship with pembrolizumab treatment [ 144 ].…”

Section: Developing Therapeutic Applications Targeting the Microbiomementioning

confidence: 99%

Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment

Kuštrimović

Bombelli

Baci

et al. 2023

IJMS

View full text Add to dashboard Cite

Growing evidence of the microbiome’s role in human health and disease has emerged since the creation of the Human Microbiome Project. Recent studies suggest that alterations in microbiota composition (dysbiosis) may play an essential role in the occurrence, development, and prognosis of prostate cancer (PCa), which remains the second most frequent male malignancy worldwide. Current advances in biological technologies, such as high-throughput sequencing, transcriptomics, and metabolomics, have enabled research on the gut, urinary, and intra-prostate microbiome signature and the correlation with local and systemic inflammation, host immunity response, and PCa progression. Several microbial species and their metabolites facilitate PCa insurgence through genotoxin-mediated mutagenesis or by driving tumor-promoting inflammation and dysfunctional immunosurveillance. However, the impact of the microbiome on PCa development, progression, and response to treatment is complex and needs to be fully understood. This review addresses the current knowledge on the host–microbe interaction and the risk of PCa, providing novel insights into the intraprostatic, gut, and urinary microbiome mechanisms leading to PCa carcinogenesis and treatment response. In this paper, we provide a detailed overview of diet changes, gut microbiome, and emerging therapeutic approaches related to the microbiome and PCa. Further investigation on the prostate-related microbiome and large-scale clinical trials testing the efficacy of microbiota modulation approaches may improve patient outcomes while fulfilling the literature gap of microbial–immune–cancer-cell mechanistic interactions.

show abstract

“…Conversely, extracellular vesicles derived from A. muciniphila can elicit cytotoxic T lymphocyte responses against PC in mice [ 20 ]. Moreover, according to one report, the clinical response to immunotherapy by PD-1 blockade of metastatic CRPC progressing on enzalutamide is associated with a decrease rather than with an increase in A. muciniphila [ 21 ], contrasting with the observation that A. muciniphila is associated with clinical responses to PD-1 blockade in other human malignancies including non-small cell lung cancer, melanoma and uroepithelial cancer [ 4 , 22 , 23 ]. Instead, the response of CRPC patients to PD-1 blockade correlated with an increase in the fecal abundance the Streptococcus salivarius [ 21 ].…”

Section: Positive Impact Of the Gut Microbiota On The Efficacy Of And...mentioning

confidence: 99%

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Terrisse¹,

Zitvogel²,

Kroemer³

2022

Microb Cell

View full text Add to dashboard Cite

Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormone-sensitive PC (HSPC) to CPRC has been explained by cancer cell-intrinsic resistance mechanisms. Recent data indicate that this transition is also marked by cancer cell-extrinsic mechanisms such as the failure of ADT-induced PC immunosurveillance, which depends on the presence of immunostimulatory bacteria in the gut. Moreover, intestinal bacteria that degrade drugs used for ADT, as well as bacteria that produce androgens, can interfere with the efficacy of ADT. Thus, specific bacteria in the gut serve as a source of testosterone, which accelerates prostate cancer progression, and men with CRPC exhibit an increased abundance of such bacteria with androgenic functions. In conclusion, the response of PC to ADT is profoundly influenced by the composition of the microbiota with its immunostimulatory, immunosuppressive and directly ADT-subversive elements.

show abstract

Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab)

Cited by 27 publications

References 54 publications

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Microbiome and Prostate Cancer: A Novel Target for Prevention and Treatment

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Contact Info

Product

Resources

About